



BROCHURE

Together for Transforming Data to Documents

Medical Writing Services

APCER Medical Writing develops regulatory documents across all phases of the product lifecycle. It delivers exceptional expertise in creating and updating a comprehensive range of clinical trial and regulatory documents, from early-phase trials through to marketing materials. Our team of highly qualified, dedicated, and experienced medical writing experts has a deep understanding across diverse therapeutic areas, ensuring your clinical programs adhere to the highest standards of quality and compliance.

With the ever-changing tapestry of regulatory guidelines, pharmaceutical companies face the significant challenge of keeping up with the demand for standardized documentation and communicating complex scientific information clearly and accurately to diverse stakeholders. APCER's experienced professionals help our clients navigate these challenges and ensure the smooth progress of their drug development programs toward successful regulatory approval. We craft flawless clinical, regulatory, and scientific documents in an end-to-end process that meets the highest industry standards, in the process, navigating regulatory hurdles with unmatched efficiency.

Key Documentation Challenges Faced by Pharmaceutical Companies



Limited medical writing expertise & skills to present complex scientific data and concepts



Unable to scale up within constrained schedules



Insufficient knowledge of guidelines and regulatory requirements



Quality issues such as inconsistency and inaccuracy leading to delay and rework

MEDICAL WRITING 1

APCER's Medical Writing Services across the Drug Life Cycle

NDA/ MAA Phase I Phase II **Post-Marketing** Pre-clinical Phase III **Development and Research documentation** Filings / Submissions Post-Marketing and Life Cycle Maintenance Post-Marketing and Filings / Submissions **Development and Research** Life Cycle Maintenance **Post-Marketing Commitments Clinical Protocols** For Innovator Companies • Early Phase/Phase IIa/IIb/III • Protocols and Reports for Phase IV • CTD Summaries & Overviews PMS studies: Observational • ISS and ISE (integrated analyses) studies (RWE), Investigator-initiated **Clinical Study Reports (Early** • Labels (drafts and updates) Phase/IIa/IIb/III) • Reference Safety Information (RSI) • Full CSRs **Product Life Cycle Maintenance** Abbreviated CSRs • Variation Filings (Label updates, • Synoptic CSRs Clinical Expert Statements, CCDS) For Generic Companies • Renewals (Clinical and non-clinical **Other Trial-related Documents** • CTD Summaries (Modules 2.6 documentation) • Investigator Brochures and 2.7) • NDA/ANDA Annual Reports • CTD Overviews (Modules 2.4 Safety Narratives and 2.5) • Informed Consent Documents • Labels (SPC and PIL; PI and **Scientific Communications** Medication Guide) **Regulatory Documents** • Manuscripts and Review articles Briefing Document • Slide Decks/Newsletters/LBL/ Bioequivalence Studies • IND/CTA or NDA/BLA/MAA Infographics/e-mailers (Protocols/ICF/CSRs) Application Posters and Abstracts Annual Reports • Educational material and Website Drug Designations Content • Pediatric Investigation Plan Clinical Trail Transparency and **Allied Services** Scientific Writing **Disclosures** • Training and Training Manuals • Congress Materials: Posters and • Trial Registration SOPs • Results Disclosures Abstracts • SRLs • Plain Language Summaries Manuscripts Medical rationales • Redaction of Clinical Documents

APCER LIFE SCIENCES

A reliable partner to help you navigate the path through drug development, licensing, marketing and life cycle maintenance

BLA = Biologics License Application

COs = Clinical Overviews

CSR = Clinical study report

CTA = Clinical Trial Application

COs = Non-clinical

CTD = Common Technical Document

SPC = Summary of product characteristics

ISS = Integrated summary of safety

ISE = Integrated summary of efficacy

PI = Prescribing information

RWE = Real-world evidence

ANDA = Abbreviated new drug application

ICF = Informed Consent Forms

IND = Investigational New Drug

PMS = Post-Marketing Surveillance

PIL = Patient information leaflet

LBL = Leave behind leaflet

CCDS = Company Core Data Sheet

NDA = New Drug Application


MAA = Marketing Authorization Application

SOP = Standard Operating Procedure

SRL = standard response letter

MEDICAL WRITING 2

Extensive Experience across Therapeutic Areas



The APCER Advantage



One-stop-solution for Medical Writing services supporting all phases of product life cycle



To keep abreast of the ever changing regulatory landscape with wide-ranging global regulatory experience from EU, USFDA, Health Canada, TGA, etc. through our customized and fully compliant services



Robust two-step review process, 100% quality check and a "first-time-right" approach to produce high-quality documents, thereby reducing the review time of clients



Impeccable quality delivered through an experienced team comprising subject matter experts (SMEs) with extensive therapeutic area expertise coupled with deep scientific knowledge



End-to-end Solutions through Integrated Regulatory Services



Specialized services with customized solutions and engagement with consultants/SMEs



A dedicated team of copyeditors and typesetters to perform a check on language, grammar, and style and ensuring e-submission readiness.

MEDICAL WRITING 3

Testimonials

- **SE** APCER Life Sciences was instrumental in our success in meeting these important Clinical Trial Disclosure compliance deadlines.
 - -Head, Clinical Trial Transparency

- **f** They are cost competetive and very, very dependable, and that is why they keep getting more and more work.
 - -Regional Head, Global Medical Writing





Together for better health Part of APC Group

APCER Life Sciences is committed to improving health in partnership with its clients. We bring together safety, medical, regulatory and technology resources to ensure that patients receive the safest, most effective therapies possible.

We are an ISO 9001:2015, ISO 27001:2022, and ISO 27701:2019 certified company.

Learn more at www.apcerls.com or contact us at one of our global offices: Americas: (+1) 609 455 1600 • Europe: (+49) 2409 725 6120 • UK: (+44) 208 326 3220 • Asia: (+91) 79 6677 8600

For Business enquiries, please email at: marketing@apcerls.com For General enquiries, please email at: info@apcerls.com